<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165646</url>
  </required_header>
  <id_info>
    <org_study_id>E3810-J081-461</org_study_id>
    <nct_id>NCT00165646</nct_id>
  </id_info>
  <brief_title>A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of
      E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux
      disease in a multicenter, randomized, double-blind, comparative study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Relief of Heartburn at Final Evaluation</measure>
    <time_frame>4 weeks</time_frame>
    <description>&quot;Heartburn diary&quot; will be given to each subject and ask him/her to keep the diary every day throughout the study period. The subject will be requested to record the occurrence of heartburn during the daytime and the nighttime in the diary. Primary End Point is the rate of complete disappearance of heartburn. The rate of heartburn do not occur in the past week will be calculated based on the diary. Participants were evaluated at week 4 about episodes of heartburn in the last 7 days</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Non-erosive Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E3810</intervention_name>
    <description>E3810 5mg: once daily orally for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E3810</intervention_name>
    <description>E3810 10mg: once daily orally for 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: once daily orally for 4 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patients to be included will be outpatients who meet all of the following criteria. No
        specific gender is asked.

        &lt;For the observation period&gt;

          1. Patients who have &quot;heartburn&quot; 2 days a week or more for consecutive weeks during 3
             weeks prior to pre-observation screening. If a day of screening and a day of starting
             observation (date of registration) are different, heartburn must continuously be
             present during the in-between period.

          2. Patients who meet both 1) and 2) below; 1) The symptom is a burning sensation arising
             from the stomach or the lower chest.

        2) The symptom tends to appear frequently or is aggravated after eating, when bending a
        body forward, and/or when pressing on the abdomen.

        (3) Patients categorized in &quot;grade M&quot; (discoloring type: minimal change) according to the
        Los Angeles System (2nd Modification) for Classification of Reflux Esophagitis.

        (4) Patients who are 20 years old or older at the time of obtaining consent. (5) Patients
        who are informed of the objective and details of the study and give written consent for
        study entry.

        &lt;For the treatment period&gt;

          1. Patients who have &quot;heartburn&quot; on 2 days a week or more in 7 days immediately before
             the treatment period (during the observation period).

          2. Patients with &quot;heartburn diary&quot; that is completely filled out for 7 days until the
             treatment period (during the observation period). If the observation period is 8 days
             or longer, those with heartburn diary of which entries are fulfilled 80% or more
             during the observation period.

          3. Patients with 80% or better drug compliance for antacids during the observation
             period.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from the study.

          1. Patients who cannot keep adequate entries of heartburn diary by themselves.

          2. Patients who strongly complain &quot;feeling of heavy stomach&quot; and/or &quot;abdominal bloating.&quot;

          3. Patients who have a complication or history of psychiatric or psychosomatic disease
             (e.g., manic-depressive psychosis, obsessive-compulsive neurosis, or others) or those
             who are on an antidepressant or anti-anxiety agent (accepted if only for a hypnotic
             treatment).

          4. Patients who have undergone Helicobacter pylori eradication therapy, and less than 6
             months have elapsed from the end of H. pylori eradication therapy to the beginning of
             the observation period. : The same day 6 months earlier, and the day at the end of 6
             months earlier if it is at the end of month.

          5. Patients with open gastric or duodenal ulcer.

          6. Patients with acute gastritis.

          7. Patients with a history of any surgical intervention that affect peptic secretion
             (e.g., upper gastrointestinal tract resection and/or vagotomy).

          8. Patients with Barrett's esophagus, esophageal stenosis, or pyloric stenosis.

          9. Patients with scleroderma.

         10. Patients with a history or complication of angina pectoris.

         11. Patients who work at night (working for a night-shift).

         12. Patients who received proton pump inhibitors (PPIs) within 3 weeks prior to
             pre-observation screening

         13. Patients who need NSAIDs (except topical preparations), steroids (except topical
             preparations), and/or aspirin treatment every day

         14. Patients receiving dialysis therapy

         15. Patients with a serious complication such as cardiovascular disease (e.g., myocardial
             infarction), hematological disorder (e.g., aplastic anemia), renal disease (e.g.,
             acute or chronic renal failure), hepatic disease (e.g., cirrhosis), or malignant
             tumor.

         16. Patients with known hypersensitivity to antacids or PPIs.

         17. Patients who are pregnant or those with childbearing potential, or those who wish to
             become pregnant or are lactating during the study period.

         18. Patients receiving another investigational drug or those who received another
             investigational drug within 6 months prior to pre-observation screening : Registration
             is allowed on the same day of 6 months earlier, and the day at the end of 6 months
             earlier if it is at the end of month.

         19. Patients who are judged to be ineligible for the study entry by the investigator or
             subinvestigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuyuki Sugisaki</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aichi-Gun</city>
        <state>Aichi-Prefecture</state>
        <zip>480-1103</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi-Prefecture</state>
        <zip>466-0065</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi-Prefecture</state>
        <zip>467-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka-Prefecture</state>
        <zip>818-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka-Prefecture</state>
        <zip>818-0067</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <state>Fukuoka-Prefecture</state>
        <zip>813-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kita-kyushu</city>
        <state>Fukuoka-Prefecture</state>
        <zip>807-1262</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi</city>
        <state>Gunma-Prefecture</state>
        <zip>371-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <state>Hiroshima-Prefecture</state>
        <zip>730-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <state>Hiroshima-Prefecture</state>
        <zip>734-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido-Prefecture</state>
        <zip>003-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido-Prefecture</state>
        <zip>060-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido-Prefecture</state>
        <zip>060-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kochi</city>
        <state>Kochi-Prefecture</state>
        <zip>780-0901</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <state>Kyoto-Prefecture</state>
        <zip>602-0000</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <state>Kyoto-Prefecture</state>
        <zip>606-8397</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandai</city>
        <state>Miyagi-Prefecture</state>
        <zip>980-0872</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi-Prefecture</state>
        <zip>984-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moriguchi</city>
        <state>Osaka-Prefecture</state>
        <zip>570-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <state>Osaka-Prefecture</state>
        <zip>530-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <state>Osaka-Prefecture</state>
        <zip>536-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <state>Osaka-Prefecture</state>
        <zip>545-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saga</city>
        <state>Saga-Prefecture</state>
        <zip>849-0937</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawaguchi</city>
        <state>Saitama-Prefecture</state>
        <zip>332-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumo</city>
        <state>Shimane-Prefecture</state>
        <zip>693-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsue</city>
        <state>Shimane-Prefecture</state>
        <zip>690-0886</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka-Prefecture</state>
        <zip>431-3125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>140-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sanyoonoda</city>
        <state>Yamaguchi-Prefecture</state>
        <zip>756-0076</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sanyoonoda</city>
        <state>Yamaguchi-Prefecture</state>
        <zip>757-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <state>Yamaguchi-Prefecture</state>
        <zip>755-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <state>Yamaguchi-Prefecture</state>
        <zip>755-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <state>Yamaguchi-Prefecture</state>
        <zip>755-0067</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <state>Yamaguchi-Prefecture</state>
        <zip>755-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>May 23, 2011</results_first_submitted>
  <results_first_submitted_qc>May 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2011</results_first_posted>
  <last_update_submitted>July 14, 2011</last_update_submitted>
  <last_update_submitted_qc>July 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Nobuyuki Sugisaki</name_title>
    <organization>Eisai Co., Ltd.</organization>
  </responsible_party>
  <keyword>non-erosive gastroesophageal reflux disease</keyword>
  <keyword>NERD</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>rabeprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was recruited at 35 centers in Japan during the period of Sep-2004 to Oct-2005.</recruitment_details>
      <pre_assignment_details>Antacid was administered 1-2 weeks for observational period (non-blind). Patients showing the resistance to antacid were transferred to treatment period (randomized double-blind) of placebo, E3810 5 or 10 mg/day for four weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>once daily orally for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>E3810 5 mg</title>
          <description>E3810 (Pariet (Rabeprazole Sodium)) 5 mg once daily orally for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>E3810 10 mg</title>
          <description>E3810 (Pariet (Rabeprazole Sodium))10 mg once daily orally for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>once daily orally for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>E3810 5 mg</title>
          <description>E3810 (Pariet (Rabeprazole Sodium)) 5 mg once daily orally for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>E3810 10 mg</title>
          <description>E3810 (Pariet (Rabeprazole Sodium))10 mg once daily orally for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="101"/>
            <count group_id="B4" value="285"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Full Analysis Set Population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.7" spread="17.0"/>
                    <measurement group_id="B2" value="46.3" spread="15.3"/>
                    <measurement group_id="B3" value="46.8" spread="15.7"/>
                    <measurement group_id="B4" value="47.6" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Relief of Heartburn at Final Evaluation</title>
        <description>“Heartburn diary” will be given to each subject and ask him/her to keep the diary every day throughout the study period. The subject will be requested to record the occurrence of heartburn during the daytime and the nighttime in the diary. Primary End Point is the rate of complete disappearance of heartburn. The rate of heartburn do not occur in the past week will be calculated based on the diary. Participants were evaluated at week 4 about episodes of heartburn in the last 7 days</description>
        <time_frame>4 weeks</time_frame>
        <population>The major endpoint of this study was between-group comparison of the complete relief of heartburn (at the completion of the treatment period) in the full analysis set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>once daily orally for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>E3810 5 mg</title>
            <description>E3810 (Pariet (Rabeprazole Sodium)) 5 mg once daily orally for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>E3810 10 mg</title>
            <description>E3810 (Pariet (Rabeprazole Sodium))10 mg once daily orally for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Relief of Heartburn at Final Evaluation</title>
          <description>“Heartburn diary” will be given to each subject and ask him/her to keep the diary every day throughout the study period. The subject will be requested to record the occurrence of heartburn during the daytime and the nighttime in the diary. Primary End Point is the rate of complete disappearance of heartburn. The rate of heartburn do not occur in the past week will be calculated based on the diary. Participants were evaluated at week 4 about episodes of heartburn in the last 7 days</description>
          <population>The major endpoint of this study was between-group comparison of the complete relief of heartburn (at the completion of the treatment period) in the full analysis set (FAS).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="34.4"/>
                    <measurement group_id="O3" value="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>once daily orally for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>E3810 5 mg</title>
          <description>E3810 (Pariet (Rabeprazole Sodium)) 5 mg once daily orally for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>E3810 10 mg</title>
          <description>E3810 (Pariet (Rabeprazole Sodium))10 mg once daily orally for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric mucosal lesion</sub_title>
                <description>These AEs occurred 23days after the end of administration.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <description>These AEs occurred 23days after the end of administration.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="91"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Laryngopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neutrophil percentage increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lymphocyte percentage decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nobuyuki Sugisaki, Study Director</name_or_title>
      <organization>Eisai Co.,Ltd. Eisai Product Creation Systems</organization>
      <phone>+81-3-3817-3908</phone>
      <email>n-sugisaki@hhc.eisai.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

